1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Anaplastic Thyroid Cancer - Pipeline Review, H1 2016

Anaplastic Thyroid Cancer - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 85 pages

Anaplastic Thyroid Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Anaplastic Thyroid Cancer - Pipeline Review, H1 2016’, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Anaplastic Thyroid Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anaplastic Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Anaplastic Thyroid Cancer - Overview 8
Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9
Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10
Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Anaplastic Thyroid Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Anaplastic Thyroid Cancer - Products under Development by Companies 14
Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15
Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16
Daiichi Sankyo Company, Limited 16
Exelixis, Inc. 17
Genelux Corporation 18
Immune Pharmaceuticals Inc. 19
Millennium Pharmaceuticals, Inc. 20
Novartis AG 21
Plexxikon Inc. 22
Anaplastic Thyroid Cancer - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
cabozantinib s-malate - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
ceritinib - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
CLM-3 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
CLM-94 - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
crolibulin - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
efatutazone - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
GLONC-2 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
GLV-1h153 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
pexidartinib - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
PLX-8394 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
sapanisertib - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Anaplastic Thyroid Cancer - Recent Pipeline Updates 57
Anaplastic Thyroid Cancer - Dormant Projects 82
Anaplastic Thyroid Cancer - Product Development Milestones 83
Featured News and Press Releases 83
Apr 18, 2013: Combination Therapy Shows Promise against Anaplastic Thyroid Cancer, Study Finds 83
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2016 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 16
Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016 17
Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H1 2016 18
Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H1 2016 19
Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 20
Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H1 2016 21
Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2016 22
Assessment by Monotherapy Products, H1 2016 23
Assessment by Combination Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 57
Anaplastic Thyroid Cancer - Dormant Projects, H1 2016 82

List of Figures
Number of Products under Development for Anaplastic Thyroid Cancer, H1 2016 8
Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 23
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.